| Medication Name
|
Trade name(s)
|
Mechanism of action
|
Current FDA Status
|
placebo-adjusted percent bodyweight lost (highest dose studied)
|
| Lorcaserin
|
Belviq
|
5-HT2C receptor agonist
|
Withdrawn for safety reasons
|
6.25 percent
|
| Sibutramine
|
Meridia
|
Serotonin–norepinephrine reuptake inhibitor
|
Withdrawn due to cardiovascular risks
|
19.7 percent
|
| Rimonabant
|
Acomplia, Zimbutli
|
Cannabinoid receptor antagonist
|
Withdrawn for safety reasons
|
2.6 to 6.3 kilograms (5.7 to 13.9 lb)
|
| Fenfluramine
|
|
Serotonin releasing agent
|
Withdrawn for safety reasons
|
-
|
| Fenfluramine/phentermine (fen-phen)
|
Pondimin
|
|
Withdrawn for safety reasons
|
13.9 percent
|
| Dexfenfluramine
|
Redux
|
Serotonin releasing agent
|
Withdrawn for safety reasons
|
3.5 kilograms (7.7 lb)
|
| 2,4-Dinitrophenol
|
|
Uncoupling agent
|
Withdrawn for safety reasons
|
17.1 pounds (7.8 kg) per patient on average (uncontrolled study)
|